KARAASLAN, Z. Et Al. 2023. Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. Northern Clinics of Istanbul , vol.10, no.3 , 341-344.

KARAASLAN, Z., YILMAZ, V., YÜCEER, H., ŞANLI, E., Akcay, H. I., Kurtuncu, M., ... Turkoglu, R.(2023). Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder. Northern Clinics of Istanbul , vol.10, no.3, 341-344.

KARAASLAN, Zerrin Et Al. "Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder," Northern Clinics of Istanbul , vol.10, no.3, 341-344, 2023

KARAASLAN, Zerrin Et Al. "Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder." Northern Clinics of Istanbul , vol.10, no.3, pp.341-344, 2023

KARAASLAN, Z. Et Al. (2023) . "Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder." Northern Clinics of Istanbul , vol.10, no.3, pp.341-344.

@article{article, author={Zerrin KARAASLAN Et Al. }, title={Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder}, journal={Northern Clinics of Istanbul}, year=2023, pages={341-344} }